Molecular Engineering of Therapeutic Cytokines

Antibodies

Rodrigo Vazquez-Lombardi¹  Brendan Roome² 

[1] id="af1-antibodies-02-00426">Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, Sydney, New South Wales 2010, Austral

关键词: immunotherapy;    cytokines;    protein engineering;    immunocytokines;    fusion proteins;   

DOI  :  10.3390/antib2030426

来源: mdpi

【 摘 要 】

Over the past three decades, a large body of work has been directed at the development of therapeutic cytokines. Despite their central role in immune modulation, only a handful of cytokine therapeutics has achieved regulatory approval. One of the major challenges associated with the therapeutic use of cytokines relates to their short serum half-life and low bioavailability. High doses are required to overcome these problems, which often result in dose-limiting toxicities. Consequently, most cytokines require protein engineering approaches to reduce toxicity and increase half-life. For this purpose, PEGylation, fusion proteins, antibody complexes and mutagenesis have been utilized. Here, we summarize past, recent and emerging strategies in this area.

【 授权许可】

CC BY   
© 2013 by the authors; licensee MDPI, Basel, Switzerland.